- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | OSR Health subsidiary completes glioblastoma vaccine analysis | 3 | Investing.com | ||
| Mo | OSR Health, Inc.: Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform | 179 | ACCESS Newswire | Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today... ► Artikel lesen | |
| OSR HEALTH Aktie jetzt für 0€ handeln | |||||
| Fr | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Fr | OSR Health, Inc.: OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment | 311 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication... ► Artikel lesen | |
| 13.07. | OSR Health, Inc.: OSR Health, A Message From the CEO | 436 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders.To Every OSR Health Shareholder:OSR Health... ► Artikel lesen | |
| 02.07. | Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target | 540 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (Nasdaq:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating... ► Artikel lesen | |
| 25.06. | OSR Health, Inc.: OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares | 422 | ACCESS Newswire | Contingent Value Rights would reward continuous holders with additional shares as the Company meets defined price milestones BELLEVUE, WA / ACCESS Newswire / June 25, 2026 / OSR Health, Inc. (NASDAQ:OSRH)... ► Artikel lesen | |
| 22.06. | OSR Holdings changes corporate name to OSR Health | 3 | Investing.com | ||
| 22.06. | OSR Health, Inc.: OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do | 344 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / June 22, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly... ► Artikel lesen | |
| 17.06. | OSR Health ändert Firmennamen - Handelssymbole an der NASDAQ bleiben unverändert | 1 | Investing.com Deutsch | ||
| 17.06. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.06. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | OSR Holdings to acquire VXM01 IP portfolio for $30 million | 2 | Investing.com | ||
| 27.05. | OSR Holdings, Inc.: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | 582 | ACCESS Newswire | Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare... ► Artikel lesen | |
| 13.05. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | OSR Holdings rules out reverse stock split amid Nasdaq compliance efforts | 3 | Investing.com | ||
| 12.05. | OSR Holdings, Inc.: CEO Statement to Shareholders | 421 | ACCESS Newswire | A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A... ► Artikel lesen | |
| 05.05. | OSR Holdings, Inc.: Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | 570 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target... ► Artikel lesen | |
| 30.04. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,273 | +3,58 % | Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why | ||
| CYTOMX THERAPEUTICS | 2,709 | 0,00 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 | ||
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 3,541 | -2,85 % | XFRA 4LN2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCAPRICOR THERAP.... ► Artikel lesen | |
| CORMEDIX | 6,686 | +1,98 % | CorMedix, Inc.: CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 | ||
| MINERVA NEUROSCIENCES | 3,456 | +0,35 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| REPLIMUNE | 10,565 | +2,13 % | XFRA 7R8: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILREPLIMUNE GR. INC... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,770 | +2,94 % | Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update | Valerio and Abivax enter into a binding term-sheet for an exclusive global research and development collaboration Under the terms of the agreement Valerio will receive an upfront payment... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,800 | -0,16 % | Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing | RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 27,300 | +0,11 % | Cool Nature übernimmt ANRO und positioniert sich als führender Maronenerzeuger | Die Unternehmensgruppe, zu der Cool Farms, der größte Kiwi-Produzent der Iberischen Halbinsel, gehört, plant die Anpflanzung von 2.000 Hektar Maronenbäumen mit einer jährlichen Produktion von 8 Millionen... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment | Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,940 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| QIAGEN | 36,385 | +1,86 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 57,98 | -0,10 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen |
OSR HEALTH INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,002 (+0,43 %) liegt der Kurs bei 0,448 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HEALTH INC finden Sie auf Wallstreet Online.